Pancreatic Ductal Adenocarcinoma Clinical Trials

49 studies are recruiting for pancreatic ductal adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

   This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcin…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Karolinska Universitetssjukhuset, Stockholm,

   Locations

   2 in total

   Run by

   GE Healthcare

   See if you can join NCT07219238 on ClinicalTrials.gov

2. Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

   Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT07199764 on ClinicalTrials.gov

3. Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

   The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06122896 on ClinicalTrials.gov

4. A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

   This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   Crossignal Therapeutics, Inc.

   See if you can join NCT06598007 on ClinicalTrials.gov

5. Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

   This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   6 in total

   Run by

   Phanes Therapeutics

   See if you can join NCT05431270 on ClinicalTrials.gov

6. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

   Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers …

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06503146 on ClinicalTrials.gov

7. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Santa Monica Hematology Oncology, Santa Monica, California

   Locations

   20 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

8. A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

   This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combinati…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Mandana Kamgar, MD

   See if you can join NCT05630989 on ClinicalTrials.gov

9. Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

   This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experimen…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cooperman Barnabas Medical Center (Saint Barnabas Medical Center), Livingston, New Jersey

   Locations

   2 in total

   Run by

   Rutgers, The State University of New Jersey

   See if you can join NCT05296421 on ClinicalTrials.gov

10. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Locations

    14 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

11. The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

    Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the bl…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Nuvance Health, Norwalk, Connecticut

    Run by

    Nuvance Health

    See if you can join NCT04406831 on ClinicalTrials.gov

12. A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer

    This clinical trial studies a new screening program to improve the early detection of sporadic pancreatic cancer in individuals with a high risk of developing pancreatic cancer. Pancreatic cancer remains one of the deadliest solid tumors, characterized by a long phase without symptoms followed by r…

    Stage

    Not phased

    Ages

    50 to 85

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07324096 on ClinicalTrials.gov

13. Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

    A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Imbert Cancer Center, Bay Shore, New York

    Locations

    7 in total

    Run by

    Northwell Health

    See if you can join NCT07163273 on ClinicalTrials.gov

14. A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

    This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06151223 on ClinicalTrials.gov

15. Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

    The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwell Health R.J. Zuckerberg Cancer Center, Lake Success, New York

    Locations

    5 in total

    Run by

    Gulam Manji

    See if you can join NCT06048484 on ClinicalTrials.gov

16. Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

    This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Jacksonville, Florida

    Locations

    25 in total

    Run by

    AstraZeneca

    See if you can join NCT06005493 on ClinicalTrials.gov

17. SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

    The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitam…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    2 in total

    Run by

    General Oncology, Inc.

    See if you can join NCT04150042 on ClinicalTrials.gov

18. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Denver, Colorado

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov

19. Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

    This study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where …

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT06600906 on ClinicalTrials.gov

20. Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

    The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT07096362 on ClinicalTrials.gov

21. UCSF PANC Cyst Registry

    Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT04291651 on ClinicalTrials.gov

22. Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

    The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Texas Health Science Center at Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06831136 on ClinicalTrials.gov

23. Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

    The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadju…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Providence Medical Foundation, Fullerton, California

    Locations

    93 in total

    Run by

    Panbela Therapeutics, Inc.

    See if you can join NCT05254171 on ClinicalTrials.gov

24. A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

    The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Karmanos Cancer Center, Detroit, Michigan

    Locations

    2 in total

    Run by

    Oncotelic Inc.

    See if you can join NCT06079346 on ClinicalTrials.gov